Harvard Catalyst Profiles

Contact, publication, and social network information about Harvard faculty and fellows.

Rationale for a Phase II Trial of Pertuzumab, a HER-2 Dimerization Inhibitor, in Patients with Non-Small Cell Lung Cancer

Johnson BE and Jänne P.A. . Rationale for a Phase II Trial of Pertuzumab, a HER-2 Dimerization Inhibitor, in Patients with Non-Small Cell Lung Cancer. Clinical Cancer Research. 2006; 14(12):4436s-4440s.


Funded by the NIH National Center for Advancing Translational Sciences through its Clinical and Translational Science Awards Program, grant number UL1TR002541.